|
|
|
|
October 14, 2022
|
J & J Vision Introduces TECNIS Symfony OptiBlue EDOF PC-IOL |
| Advertisement |
 
|
Johnson & Johnson Vision has announced availability of a presbyopia-correcting intraocular lens (PC-IOL), the TECNIS Symfony OptiBlue. A press release says, “This extended depth-of-focus (EDOF) lens expands presbyopia correction to more patients and joins TECNIS Synergy IOL, a high-performance hybrid lens designed for spectacle independence, in the InteliLight portfolio.” The release explains that InteliLight is an innovative combination of three J & J Vision proprietary technologies: violet-light filter, echelette design, and achromatic technology. The TECNIS PC-IOL is now available for ophthalmologists to use in the U.S. and select countries in EMEA. More information can be found at https://www.prnewswire.com/news-releases/johnson--johnson-vision-introduces-all-purpose-edof-tecnis-symfony-optiblue-iol-the-latest-pc-iol-powered-by-intelilight-technology-301634976.html.
|
Visus Expands Ophthalmic Drug Development Portfolio With Acquisition of ViewPoint |
| Visus Therapeutics has expanded its pipeline by acquiring all patents and other assets of ViewPoint Therapeutics. A press release says ViewPoint, which was founded in 2014, discovered and developed alpha-crystallin aggregation inhibitors as investigational non-surgical treatments to correct protein misfolding in the lens. Protein misfolding reduces lens elasticity and clarity leading to presbyopia and cataract. Alpha-crystallin aggregation inhibitors are intended to restore elasticity and lens clarity, potentially reversing presbyopia and cataracts without the need for surgery. More information can be found at https://www.businesswire.com/news/home/20220928005571/en/Visus-Therapeutics-Expands-Ophthalmic-Drug-Development-Portfolio-With-Acquisition-of-ViewPoint-Therapeutics%E2%80%99-Assets.
|
Radius XR Brings Together Multimodal Diagnostics, Practice Management, And Patient Engagement For The First Time |
| IrisVision co-founder and CEO Ammad Khan has introduced a new company, Radius XR. A press release says the new company builds on the therapeutic legacy of IrisVision by introducing diagnostic capability to the proprietary VR/AR assistive device. The release says “the fashion-forward design of Radius XR is a significant leap forward in wearable devices, with the look and feel of a pair of fashionable sunglasses.” It also says, “The small, lightweight design overcomes the challenges of expensive and bulky legacy devices that force patients to sit in uncomfortable positions for testing. Exams can be conducted beyond exam lanes, allowing a patient’s exam in nontraditional spaces like waiting rooms, remote offices, and lobbies,” and “The platform includes a Business Suite of management tools that streamline patient check-in, enable staff to customize the experience for multiple patients, and make it easier for eyecare professionals to manage business aspects critical to their practice's ongoing success.” More information can be found at https://www.businesswire.com/news/home/20220928005007/en/Radius-XR-a-new-fashion-forward-wearable-technology-brand-brings-together-multimodal-diagnostics-practice-management-and-patient-engagement-for-the-first-time.
|
Eye Care Research Informs Major WHO Report |
| Research recently published in The Lancet Global Health reveals that less than half of people over 50 worldwide have received spectacles or contact lenses needed to correct refractive error, according to a press release. The release says the research informs a major World Health Organization (WHO) report on eye care. The study was carried out by the Vision Loss Expert Group, led by Professor Rupert Bourne, of Anglia Ruskin University (ARU) and Cambridge University Hospitals. According to the press release, researchers analyzed data from 169 different studies from across the world to calculate figures in several defined regions for treatment coverage of distance and near refractive error, and found that while adequate treatment coverage of distance refractive error (myopia, astigmatism, or moderate to severe hyperopia) had increased by 19% since 2000, only 43% of all adults over the age of 50 are receiving simple treatments for these conditions, with the number at 21% coverage for those with presbyopia. The study also highlighted a gender gap in all defined regions of the world, with lower levels of coverage in women. More information can be found at https://www.eurekalert.org/news-releases/967423.
|
Beijing Oasis Hospital and Zeiss unveil Presbyopic Correction High-End Medical Establishment |
| Beijing Oasis Hospital and Zeiss have unveiled a Presbyopic Correction High-End Medical Establishment in Beijing. According to a press release, the facility will provide services for middle-aged and elderly people who are troubled by presbyopia, cataracts, and high myopia to realize high-definition middle and near vision as well as distance vision. The release says the launch is “an opportunity for the hospital to share the model, and to improve the public's awareness of the visual concept of the whole process…” More information can be found at https://www.globaltimes.cn/page/202209/1276469.shtml.
|
|
|
